Vanguard Asset Management
TRAX

Vanguard Asset Management’s First Tracks Biotherapeutics TRAX Stock Holding History

Vanguard Asset Management’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$405K Buy
+20,146
New +$377K ﹤0.01% 2262

Other funds holding TRAX

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Asset Management's TRAX Position: Q2 2026 in Review

Vanguard Asset Management opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 20,146 shares worth $405K. The stake represents ﹤0.01% of the portfolio and ranks #2262 among its holdings.

136 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • Vanguard Asset Management held 20,146 shares of First Tracks Biotherapeutics worth $405K as of Q2 2026.
  • First Tracks Biotherapeutics was a new Vanguard Asset Management position in Q2 2026.
  • First Tracks Biotherapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2262 holding.
  • 136 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.